December 29, 2020

Lung Cancer Conference

Molecular Therapeutics in Non-Small Cell Lung Cancer:

A Virtual International Conference

——————————————————————————————————–

February 28th, 2021

7:15 am – 10:20 am PST

Held Virtually on Zoom


Activity Overview

The clinical management of lung cancer is advancing at a rapid pace.  In particular, the identification of driver mutations and delineation of the molecular signature of lung cancers have resulted in significant improvements in the front-line treatment of both localized and advanced lung adenocarcinomas. ‘Molecular Therapeutics in Non-Small Cell Lung Cancer: A Virtual International Conference’ is a CME-accredited virtual conference which brings together the leading experts from around the world to discuss recent advances in the management of non-small cell lung cancer with a focus on biomarker-driven therapies, immuno-oncology, and clinical applications of the recent advances in non-small cell lung cancer, especially adenocarcinoma histology. This meeting will provide an opportunity to hear from the leading national and international experts on how recently published data would change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of non-small cell lung cancers in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Advances in the diagnosis & identification of molecular driver mutations
  • Choice and sequencing of therapeutic options based on molecular mutation changes
  • Use of molecular treatments in the adjuvant/curative setting
  • Trends in the use of checkpoint inhibitors in curative and palliative therapy

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Understand the nuances of the use of plasma- vs tissue-based molecular diagnostic testing
  • Review recent data on the use of molecular targeted therapy in the adjuvant setting
  • Integrate emerging data on the use of newly-available driver mutation testing and the targeted therapies available
  • Review the newest data on the therapeutic uses of checkpoint inhibitor therapy.

Target Audience

This activity is directed toward medical oncologists who treat patients with lung cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of lung cancer are also invited to participate.


Accreditation Statement

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

ABSM Maintenance of Certificate Recognition Statement: 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Contact Hours 

Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2 Contact Hours.

Faculty

Dr. Joe Rosales

Virginia Mason Medical Center